Evidence map›Paper›PMID 42787717›Full record

ArticleClinical hematology international2026

Transplant outcomes after intensive chemotherapy or venetoclax plus azacitidine in acute myeloid leukemia: a multicenter retrospective study in Japan.

Hiroyuki Muranushi, Junya Kanda, Tadakazu Kondo, Yasuyuki Arai, Ikue Okamura-Shiki, Takashi Ikeda, Hiroki Amagase, Takehiro Okuda, Daishi Nakagawa, Takeshi Maeda and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical hematology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Hiroyuki MuranushiDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.ORCID https://orcid.org/0000-0003-3195-2322
Junya KandaDepartment of Hematology, Graduate School of Medicine Kyoto University, Kyoto, Japan.
Tadakazu KondoDepartment of Hematology, Graduate School of Medicine Kyoto University, Kyoto, Japan.
Yasuyuki AraiDepartment of Hematology, Graduate School of Medicine Kyoto University, Kyoto, Japan.
Ikue Okamura-ShikiDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Nagaizumi-cho, Japan.
Takashi IkedaDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Nagaizumi-cho, Japan.
Hiroki AmagaseDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Takehiro OkudaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Daishi NakagawaDepartment of Hematology, Graduate School of Medicine Kyoto University, Kyoto, Japan.
Takeshi MaedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Yasunori UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kazuhiro YagoDepartment of Hematology, Shizuoka General Hospital, Shizuoka, Japan.
Tomoharu TakeokaDivision of Hematology and Immunology, Japanese Red Cross Otsu Hospital, Otsu, Japan.
Mutsumi OkadaDepartment of Hematology, Takatsuki Red Cross Hospital, Takatsuki, Japan.
Yasuko MiyaharaDepartment of Hematology, Kyoto City Hospital, Kyoto, Japan.
MItsumasa WatanabeDepartment of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Nobuyoshi ArimaDepartment of Hematology, Shinko Hospital, Kobe, Japan.
Toshiyuki KitanoDepartment of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan.
Masakatsu HishizawaDepartment of Hematology, Kyoto Katsura Hospital, Kyoto, Japan.
Katsuhiro IoDepartment of Hematology, Kansai Electric Power Hospital, Osaka, Japan.
Satoko OkaDepartment of Hematology, Japan Red Cross Society Wakayama Medical Center, Wakayama, Japan.
Kosuke AsagoeDepartment of Hematology, Shiga General Hospital, Moriyama, Japan.
Takashi AkasakaDepartment of Hematology, Tenri Hospital, Tenri, Japan.
Kouhei YamashitaKyoto University.
Akifumi Takaori-KondoDepartment of Hematology, Graduate School of Medicine Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present retrospective multicenter study in Japan evaluated the role of venetoclax plus azacitidine (V/A) before first allogeneic hematopoietic stem cell transplantation (SCT) in 144 transplant-eligible acute myeloid leukemia (AML). Thirty-seven patients received V/A prior to SCT, mainly as salvage therapy for refractory and adverse-risk AML. Patients were classified into four groups according to remission status at SCT and V/A use. The 1-year overall survival (OS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) of those who achieved complete remission (CR) with intensive chemotherapy (IC) were 93%, 5% and 4%, respectively. The 1-year OS, CIR and NRM of those who were refractory/intolerant to IC and achieved CR with V/A were 93%, 7% and 7%, respectively. The 1-year OS, CIR and NRM of those who were refractory to IC and proceeded directly to SCT were 52%, 54% and 13%, respectively. The 1-year OS, CIR and NRM of those who were refractory/intolerant to IC and refractory to V/A were 41%, 39% and 29%, respectively. Overall, use of V/A prior to SCT salvaged some AML patients who were refractory/intolerant to IC, and the transplant outcomes of these patients were favorable. Further studies are needed to optimize treatment for AML prior to SCT.

Indexed as

Acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationazacitidinevenetoclax

Identifiers

PMID42787717
PMCPMC13602127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.